Background: Pre-eclampsia is a pregnancy-specific disorder that has a worldwide prevalence of 5-15%. It is one of the main causes of maternal and perinatal morbidity and mortality globally and accounts for 50000–60000 deaths annually, with a predominance in the low- and middle-income countries. There is a great need to have a test for predication of women at high risk of developing preeclampsia.
Aim:This work aimed to assess the accuracy of maternal serum Cff-DNA concentration levels in primigravidas 10-20 weeks gestation as a predictive test for the development of preeclampsia.
Materials and Methods: A nested case-control study was conducted on 26 patients with PE and 26 matched controls rimigravidas in 10-20 weeks gestation recruited from Ain-Shams University Maternity Hospital. Laboratory work was done in Ali Khalifa laboratory of the biochemistry department, Faculty of Medicine, Ain-Shams University.
Results: The study showed a statistically significant increase median of severe preeclampsia compared to non-severe preeclampsia and control group according to cff-DNA (GE/ml). Also the study results revealed a statistically significant increase median of preeclampsia group compared to control group according to BMI, GA (wks), SBP and DBP,
Conclusion: Cff-DNA quantification can be considered as a promising marker for preeclampsia prediction, especially for the development of early-onset or severe preeclampsia.